# Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma

> **NCT04864522** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **University of Virginia**

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** SLAMF7 FPBMC

## Key facts

- **NCT ID:** NCT04864522
- **Lead sponsor:** University of Virginia
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-08
- **Primary completion:** 2023-11
- **Final completion:** 2023-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Slow accrual due to a crowded field of effective drugs by the time the study opened
- **Last updated:** 2023-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04864522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04864522, "Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04864522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*